Navigation Links
MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:3/11/2008

Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX releases CEO message #22
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
4. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
5. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
8. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. NeoStem to Present at Third Annual Stem Cell Summit in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... --  MedyMatch Technology Ltd ., the data analytics healthcare company ... tools in the emergency room, announced today that it has ... Industries (IATI) BioMed Conference. The Conference is ... Life Sciences and Technology Week, and is being held May ... Tel Aviv, Israel . Gene Saragnese , ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and ... the South Texas Blood & Tissue Center, blood donations are on the decline. In fact, ... they are down 21 percent in South Texas in the last four years alone. , ...
(Date:5/23/2016)... -- Oxitec CEO Hadyn Parry will ... ET before the United States House Committee on Science, Space ... in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has ... Trials in Brazil , Panama ...
(Date:5/23/2016)... Alto, CA (PRWEB) , ... May 23, 2016 ... ... and public interest organization focused on molecular nanotechnology, announced the winners for the ... of pioneer physicist Richard Feynman, are given in two categories, one for experiment ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):